Literature DB >> 1929398

Purification of human cytidine deaminase: molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs.

T Cacciamani1, A Vita, G Cristalli, S Vincenzetti, P Natalini, S Ruggieri, A Amici, G Magni.   

Abstract

Cytidine deaminase has been purified to homogeneity from human placenta by a rapid and efficient procedure consisting of affinity chromatography followed by hydrophobic interaction chromatography. The final enzyme preparation showed a specific activity of 64.1 units/mg, corresponding to about 46,000-fold purification with respect to the crude extract. The enzyme is a 52-kDa oligomeric protein composed of four apparently identical subunits. The acidic isoelectric point is 4.5. The enzyme's stability is strictly dependent on the presence of reducing agents. Amino acid analysis reveals the presence of five thiol groups per monomer which cannot be titrated by Ellman's reagent in the native enzyme. However, the presence of sulfhydryl groups involved in the catalytic activity was evidenced by the inhibition exerted by p-chloromercuribenzoate and heavy metal ions. In addition, the protection effected by the substrate against the p-chloromercuribenzoate inhibition and the competitive inhibition exerted by 5-(chloromercuri)cytidine suggest the presence of a thiol group(s) in the catalytic site of the enzyme. pH studies have shown that the rapid decline of activity occurring at pH 4.5 might result from the protonation of the pyrimidine ring at the N-3 position. The enzyme catalyzes the deamination of cytidine, deoxycytidine, and several analogs, including antineoplastic agents, thus abolishing their pharmacological activity. Therefore, several pyrimidine nucleoside analogs have been tested as potential inhibitors of the enzyme. The competitive inhibition exerted by cytidine analogs having the ribose moiety replaced by aliphatic chains is interesting.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929398     DOI: 10.1016/0003-9861(91)90543-r

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

3.  Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening.

Authors:  Stefano Costanzi; Santiago Vilar; Daniela Micozzi; Francesco M Carpi; Giulio Ferino; Alberto Vita; Silvia Vincenzetti
Journal:  ChemMedChem       Date:  2011-05-19       Impact factor: 3.466

4.  PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population.

Authors:  Francesco M Carpi; Silvia Vincenzetti; Daniela Micozzi; Alberto Vita; Valerio Napolioni
Journal:  Mol Biol Rep       Date:  2009-11-26       Impact factor: 2.316

5.  Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Authors:  Hamza Mameri; Ivan Bièche; Didier Meseure; Elisabetta Marangoni; Géraldine Buhagiar-Labarchède; André Nicolas; Sophie Vacher; Rosine Onclercq-Delic; Vinodh Rajapakse; Sudhir Varma; William C Reinhold; Yves Pommier; Mounira Amor-Guéret
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

6.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.

Authors:  Deepika Bhatla; Robert B Gerbing; Todd A Alonzo; Heather Conner; Julie A Ross; Soheil Meshinchi; Xiaowen Zhai; Tiffany Zamzow; Parinda A Mehta; Hartmut Geiger; John Perentesis; Stella M Davies
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

7.  Cytidine deaminase activity increases in the blood of breast cancer patients.

Authors:  Géraldine Buhagiar-Labarchède; Rosine Onclercq-Delic; Sophie Vacher; Frédérique Berger; Ivan Bièche; Dominique Stoppa-Lyonnet; Mounira Amor-Guéret
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

8.  DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy.

Authors:  Haejeong Heo; Jong-Hwan Kim; Seon-Young Kim; Mirang Kim; Hyun Jung Lim; Jeong-Hwan Kim; Miso Kim; Jaemoon Koh; Joo-Young Im; Bo-Kyung Kim; Misun Won; Ji-Hwan Park; Yang-Ji Shin; Mi Ran Yun; Byoung Chul Cho; Yong Sung Kim
Journal:  Exp Mol Med       Date:  2022-08-23       Impact factor: 12.153

9.  Synthesis and conformational analysis of locked carbocyclic analogues of 1,3-diazepinone riboside, a high-affinity cytidine deaminase inhibitor.

Authors:  Olaf R Ludek; Gottfried K Schroeder; Chenzhong Liao; Pamela L Russ; Richard Wolfenden; Victor E Marquez
Journal:  J Org Chem       Date:  2009-08-21       Impact factor: 4.354

10.  Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs.

Authors:  Johan Vande Voorde; Peter Vervaeke; Sandra Liekens; Jan Balzarini
Journal:  FEBS Open Bio       Date:  2015-08-03       Impact factor: 2.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.